Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
01:52pm, Wednesday, 10'th Jun 2026
Capricor Therapeutics, Inc. (CAPR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Capricor Therapeutics to Present at Upcoming Investor Conferences
09:25am, Monday, 08'th Jun 2026
SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announ
Capricor: I Rate It A Buy After Stress-Testing The Sell Thesis
04:43am, Wednesday, 03'rd Jun 2026
Capricor is rated a speculative Buy ahead of its August 22 PDUFA for deramiocel in Duchenne muscular dystrophy. Recent HOPE-3 data disclosures address most prior concerns about primary and cardiac end
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
10:50pm, Tuesday, 12'th May 2026
Capricor Therapeutics, Inc. (CAPR) Q1 2026 Earnings Call Transcript
Capricor Therapeutics Q1 Earnings Call Highlights
06:08pm, Tuesday, 12'th May 2026
Capricor Therapeutics NASDAQ: CAPR said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 12'th May 2026
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb
Capricor's Insider Just Sold Big — Her Options Tell the rest of the Story
07:01am, Sunday, 10'th May 2026
Focused on advanced cell therapies for rare diseases, this biotech firm reported a notable insider sale in its latest SEC filing.
Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy
09:34am, Friday, 08'th May 2026
Capricor Therapeutics Inc. (NASDAQ:CAPR) on Thursday filed a lawsuit against Nippon Shinyaku Co., Ltd. and its U.S. subsidiary NS Pharma, Inc., alleging that flaws in the companies' U.S. distribution
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12
04:05pm, Monday, 04'th May 2026
– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transform
Capricor Therapeutics (NASDAQ:CAPR) CFO Anthony Bergmann Sells 25,000 Shares of Stock
04:48am, Friday, 03'rd Apr 2026
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) CFO Anthony Bergmann sold 25,000 shares of the firm's stock in a transaction dated Tuesday, March 31st. The stock was sold at an average pr
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 61,265 Shares
04:48am, Friday, 03'rd Apr 2026
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) Director Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stoc
Capricor Therapeutics (NASDAQ:CAPR) Director Karimah Es Sabar Sells 53,735 Shares of Stock
04:48am, Friday, 03'rd Apr 2026
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report) Director Karimah Es Sabar sold 53,735 shares of the company's stock in a transaction dated Wednesday, April 1st. The stock was sold at an a
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50 Day Moving Average – What’s Next?
03:13am, Tuesday, 31'st Mar 2026
Capricor Therapeutics, Inc. (NASDAQ: CAPR - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $26.80 and traded
Contrasting Zimmer Biomet (NYSE:ZBH) and Capricor Therapeutics (NASDAQ:CAPR)
01:42am, Sunday, 15'th Mar 2026
Capricor Therapeutics (NASDAQ: CAPR - Get Free Report) and Zimmer Biomet (NYSE: ZBH - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two business
Capricor: Moving To 'Buy' Rating As New PDUFA Date Is Set For Deramiocel
04:11pm, Friday, 13'th Mar 2026
Capricor Therapeutics is upgraded from 'Hold' to 'Buy' following FDA acceptance of the HOPE-3 clinical study report for Deramiocel in DMD cardiomyopathy. The FDA lifted the Complete Response Letter an
